FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2743804580> ?p ?o ?g. }

• W2743804580 endingPage "290" @default.
• W2743804580 startingPage "283" @default.
• W2743804580 abstract "The study's purpose was to assess safety and efficacy of escalating doses of weekly GEN-1 with pegylated liposomal doxorubicin (PLD) in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers (EOC).Patients had persistent or recurrent platinum-resistant EOC. The trial was a standard 3+3 phase I dose escalation design with patients receiving intravenous PLD 40mg/m2 (dose level 1 and 2) or 50mg/m2 (dose level 3) every 28days and intraperitoneal GEN-1 at 24mg/m2 (dose level 1) or 36mg/m2 (dose level 2 and 3) on days 1, 8, 15, and 22 of a 28day cycle. Cycles were repeated every 28days until disease progression. Patients were monitored for toxicity, clinical efficacy, and evidence of systemic and intraperitoneal immunologic effect.Sixteen evaluable patients received a median of 4cycles (range 1-8). No dose limiting toxicities were found. The adverse side effects were 4 grade 3 anemia, 2 grade 3 abdominal pain, 7 grade 3 neutropenia, and 2 grade 4 neutropenia. A clinical benefit of 57.1% (PR=21.4%; SD=35.7%) was found in the 14 patients with measurable disease. The highest number of partial responses (28.6%) and stable disease (57.1%) were found at dose level 3. The maximum tolerated dose was not reached. Increases in IL-12, IFN-γ, and TNF-α levels were found in peritoneal fluid following GEN-1 treatment.GEN-1 in combination with PLD has encouraging clinical benefit and biological activity in recurrent or persistent EOC and warrants further investigation with escalating doses of GEN-1." @default.
• W2743804580 created "2017-08-17" @default.
• W2743804580 creator A5009400324 @default.
• W2743804580 creator A5009816072 @default.
• W2743804580 creator A5016917647 @default.
• W2743804580 creator A5019216768 @default.
• W2743804580 creator A5024497385 @default.
• W2743804580 creator A5027894385 @default.
• W2743804580 creator A5032022793 @default.
• W2743804580 creator A5047292923 @default.
• W2743804580 creator A5059860532 @default.
• W2743804580 creator A5069337573 @default.
• W2743804580 creator A5071711245 @default.
• W2743804580 date "2017-11-01" @default.
• W2743804580 modified "2023-10-17" @default.
• W2743804580 title "A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study" @default.
• W2743804580 cites W1507883482 @default.
• W2743804580 cites W1512465947 @default.
• W2743804580 cites W1539670786 @default.
• W2743804580 cites W1592995642 @default.
• W2743804580 cites W1957147460 @default.
• W2743804580 cites W1960327677 @default.
• W2743804580 cites W1975836245 @default.
• W2743804580 cites W1976051281 @default.
• W2743804580 cites W1995272148 @default.
• W2743804580 cites W2019607817 @default.
• W2743804580 cites W2028363781 @default.
• W2743804580 cites W2031708783 @default.
• W2743804580 cites W2038430114 @default.
• W2743804580 cites W2047071614 @default.
• W2743804580 cites W2049567202 @default.
• W2743804580 cites W2081985803 @default.
• W2743804580 cites W2101332957 @default.
• W2743804580 cites W2104849855 @default.
• W2743804580 cites W2107457010 @default.
• W2743804580 cites W2115499099 @default.
• W2743804580 cites W2120026414 @default.
• W2743804580 cites W2121046520 @default.
• W2743804580 cites W2135747342 @default.
• W2743804580 cites W2139060364 @default.
• W2743804580 cites W2139316892 @default.
• W2743804580 cites W2140114661 @default.
• W2743804580 cites W2143145234 @default.
• W2743804580 cites W2146284678 @default.
• W2743804580 cites W2150452646 @default.
• W2743804580 cites W2161066045 @default.
• W2743804580 cites W2166937531 @default.
• W2743804580 cites W2202035925 @default.
• W2743804580 cites W2495055056 @default.
• W2743804580 cites W2794166407 @default.
• W2743804580 cites W1951700319 @default.
• W2743804580 doi "https://doi.org/10.1016/j.ygyno.2017.08.001" @default.
• W2743804580 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5704992" @default.
• W2743804580 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28802766" @default.
• W2743804580 hasPublicationYear "2017" @default.
• W2743804580 type Work @default.
• W2743804580 sameAs 2743804580 @default.
• W2743804580 citedByCount "32" @default.
• W2743804580 countsByYear W27438045802017 @default.
• W2743804580 countsByYear W27438045802018 @default.
• W2743804580 countsByYear W27438045802019 @default.
• W2743804580 countsByYear W27438045802020 @default.
• W2743804580 countsByYear W27438045802021 @default.
• W2743804580 countsByYear W27438045802022 @default.
• W2743804580 countsByYear W27438045802023 @default.
• W2743804580 crossrefType "journal-article" @default.
• W2743804580 hasAuthorship W2743804580A5009400324 @default.
• W2743804580 hasAuthorship W2743804580A5009816072 @default.
• W2743804580 hasAuthorship W2743804580A5016917647 @default.
• W2743804580 hasAuthorship W2743804580A5019216768 @default.
• W2743804580 hasAuthorship W2743804580A5024497385 @default.
• W2743804580 hasAuthorship W2743804580A5027894385 @default.
• W2743804580 hasAuthorship W2743804580A5032022793 @default.
• W2743804580 hasAuthorship W2743804580A5047292923 @default.
• W2743804580 hasAuthorship W2743804580A5059860532 @default.
• W2743804580 hasAuthorship W2743804580A5069337573 @default.
• W2743804580 hasAuthorship W2743804580A5071711245 @default.
• W2743804580 hasBestOaLocation W27438045802 @default.
• W2743804580 hasConcept C126322002 @default.
• W2743804580 hasConcept C141071460 @default.
• W2743804580 hasConcept C143998085 @default.
• W2743804580 hasConcept C197934379 @default.
• W2743804580 hasConcept C203092338 @default.
• W2743804580 hasConcept C2775883341 @default.
• W2743804580 hasConcept C2776694085 @default.
• W2743804580 hasConcept C2777063308 @default.
• W2743804580 hasConcept C29730261 @default.
• W2743804580 hasConcept C31760486 @default.
• W2743804580 hasConcept C535046627 @default.
• W2743804580 hasConcept C71924100 @default.
• W2743804580 hasConcept C90924648 @default.
• W2743804580 hasConcept C98274493 @default.
• W2743804580 hasConceptScore W2743804580C126322002 @default.
• W2743804580 hasConceptScore W2743804580C141071460 @default.
• W2743804580 hasConceptScore W2743804580C143998085 @default.
• W2743804580 hasConceptScore W2743804580C197934379 @default.
• W2743804580 hasConceptScore W2743804580C203092338 @default.
• W2743804580 hasConceptScore W2743804580C2775883341 @default.

• next